Angiosarcoma
MONDO:0016982A malignant tumor arising from the endothelial cells of the blood vessels. Microscopically, it is characterized by frequently open vascular anastomosing and branching channels. The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei. Angiosarcomas most frequently occur in the skin and breast. Patients with long-standing lymphedema are at increased risk of developing angiosarcoma.
Also known as: angiosarcoma, angiosarcoma (disease), blood vessel sarcoma, hemangiosarcoma, hemangiosarcoma, malignant, malignant angioendothelioma, malignant hemangioendothelioma, sarcoma of blood vessel
2895 clinical trials for this condition and its sub-types, 37 tagged with Angiosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Angiosarcoma
-
Kaposi's sarcoma 45 trials
4 sub-types
- Classic Kaposi sarcoma 3 trials
- Endemic Kaposi sarcoma 1 trial
- Iatrogenic Kaposi's sarcoma 1 trial
- Colorectal Kaposi sarcoma 0 trials Sub-types →
-
Skin angiosarcoma 6 trials
-
Breast angiosarcoma 1 trial
-
Angiosarcoma of the scalp 0 trials
-
Aorta angiosarcoma 0 trials
-
Bone angiosarcoma 0 trials
-
Central nervous system angiosarcoma 0 trials
-
Conventional angiosarcoma 0 trials
-
Gallbladder angiosarcoma 0 trials
-
Liver angiosarcoma 0 trials
-
Mediastinum angiosarcoma 0 trials
-
Ovarian angiosarcoma 0 trials
-
Pediatric angiosarcoma 0 trials
-
Prostate angiosarcoma 0 trials
-
Pulmonary artery leiomyosarcoma 0 trials
-
Pulmonary vein leiomyosarcoma 0 trials
-
Spleen angiosarcoma 0 trials
-
Superior vena cava angiosarcoma 0 trials
1 sub-type
- Superior vena cava leiomyosarcoma 0 trials
-
Thyroid gland angiosarcoma 0 trials
Most studied deeper sub-types
-
Experimental cancer drug OMX-0407 trial halted early
Disease control Stopped earlyThis early-phase trial tested OMX-0407, a new drug that blocks certain enzymes, in 68 adults with advanced solid tumors that had stopped responding to other treatments. The study aimed to find a safe dose and check if the drug could shrink tumors. However, the trial was terminate…
Phase 1/2 • Sponsor: iOmx Therapeutics AG • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Immunotherapy drug sintilimab takes on rare blood vessel cancer
Disease control Stopped earlyThis phase 2 trial tests whether sintilimab, an immunotherapy drug, can help control angiosarcoma—a rare cancer of the blood vessels—that is advanced, has spread, or has returned. Participants receive sintilimab intravenously, and the study measures how many have no cancer growth…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC